ECOG-ACRIN Cancer Research Group

ECOG-ACRIN Cancer Research Group is a National Cancer Institute (NCI)-designated cooperative group that designs and conducts cancer research trials across a global network of institutions. Formed in 2012 through the merger of two long-standing groups, the Eastern Cooperative Oncology Group (ECOG) and the American College of Radiology Imaging Network (ACRIN), it integrates therapeutic and diagnostic imaging research. The group's mission is to reduce cancer-related mortality through the development of improved prevention, diagnostic, and treatment strategies. Its work spans a wide spectrum of malignancies, leveraging expertise from thousands of investigators across North America and internationally.

History and formation

The group's origins trace back to the founding of the Eastern Cooperative Oncology Group in 1955 as part of the National Cancer Institute's early efforts to coordinate multi-institutional clinical trials. Similarly, the American College of Radiology Imaging Network was established in 1999 to advance the science of medical imaging within oncology. The strategic merger in 2012 was driven by the National Cancer Institute's transformative initiative to consolidate the national cooperative group program, aiming to enhance efficiency and foster integrated research. This consolidation, which also saw the formation of groups like the NRG Oncology consortium, reflected a broader shift in biomedical research towards multidisciplinary collaboration. The merger uniquely combined ECOG's deep legacy in phase III trial development with ACRIN's pioneering work in biomarker validation and imaging biomarkers.

Organizational structure and leadership

The organization is governed by a steering committee co-chaired by a group chair from the therapeutic research tradition and a principal investigator from the imaging research tradition. Notable past and present leaders include Peter J. O'Dwyer of the University of Pennsylvania and Mitchell D. Schnall of the Perelman School of Medicine. Scientific oversight is divided into several core committees, including the Therapeutic Studies Program, the Imaging Research Program, and the Cancer Control and Outcomes Program. The operational backbone includes a statistical and data management center historically located at the Dana–Farber Cancer Institute and the Frontier Science & Technology Research Foundation. Its network encompasses over 1,200 member sites, including academic centers like the Mayo Clinic and Memorial Sloan Kettering Cancer Center, as well as community hospitals across the United States and international partners.

Major clinical trials and research programs

The group has conducted numerous landmark studies that have reshaped clinical practice. In breast cancer, the TAILORx trial definitively established the utility of the Oncotype DX genomic test for guiding chemotherapy decisions. In lung cancer, the EA5142 trial investigated the role of adjuvant therapy with nivolumab following chemoradiation. Pioneering imaging research includes the National Lung Screening Trial (NLST), co-led with the American College of Radiology, which demonstrated the mortality benefit of low-dose computed tomography screening. Other significant studies span prostate cancer, such as trials evaluating active surveillance, and melanoma, including investigations of immunotherapy combinations. The group also maintains a strong portfolio in cancer prevention and survivorship research.

Impact on cancer treatment and patient care

Findings from its trials have directly informed National Comprehensive Cancer Network guidelines and U.S. Food and Drug Administration approvals for new therapies and diagnostic tools. The TAILORx results alone spared tens of thousands of women with hormone receptor-positive disease from unnecessary chemotherapy. The National Lung Screening Trial led to formal screening recommendations from the U.S. Preventive Services Task Force, transforming early detection for high-risk individuals. By rigorously validating imaging protocols and radiomics, the group has helped standardize response evaluation criteria in solid tumors (RECIST) assessments globally. Its integrated research model has accelerated the development of precision medicine approaches, particularly in tailoring treatments based on genetic sequencing and PET scan results.

Funding and collaborations

Primary funding is provided through a National Cancer Institute cooperative group grant, specifically the NCI Community Oncology Research Program (NCORP) and the Cancer Moonshot initiative. Additional support comes from pharmaceutical industry partnerships, foundations like the Breast Cancer Research Foundation, and grants from the Patient-Centered Outcomes Research Institute (PCORI). The group maintains critical collaborative agreements with other NCI networks, including the SWOG Cancer Research Network and the Alliance for Clinical Trials in Oncology. It is also a founding member of the International Kidney Cancer Coalition and partners with the European Organisation for Research and Treatment of Cancer on select global trials. These partnerships enable the large-scale, diverse patient enrollment necessary for definitive practice-changing studies.

Category:Medical and health organizations based in Pennsylvania Category:Cancer research organizations Category:Clinical research organizations in the United States